Hematology

Latest News

Modern Medical Technologies | Image credit: Prostock-studio - stock.adobe.com
Using AI, Socioeconomic Factors to Predict Outcomes After Allo-SCT for AML

August 16th 2025

Artificial intelligence (AI) and socioeconomic factors enhance risk stratification for patients with acute myeloid leukemia (AML) post transplant, aiming to reduce hospital readmissions and disease progression.

The rarity of PH in MPN/AML, coupled with variable mechanisms and response to therapy, makes standardized risk tools and protocols difficult to implement. | Image Credit: Dr_Microbe - stock.adobe.com
AML Relapse Mirrors Pulmonary Hypertension Worsening in Rare Case

August 14th 2025

Patients who would be high-risk based on conventional assessments tended to have higher median QRISK3 scores in the study. | Image credit: Eleni - stock.adobe.com
QRISK3 Tool Predicts Thrombotic Events in ET, PV

August 8th 2025

BRUIN CLL-314 was the first-ever head-to-head trial of pirtobrutinib versus ibrutinib that included treatment-naive patients. | Image credit: fotogurmespb - stock.adobe.com
New Pirtobrutinib Data Compare Favorably With Ibrutinib in CLL/SLL

August 7th 2025

MM Guidelines Update | Image Credit: Maggie-sora.chatgpt.com
Linvoseltamab Added as Preferred Agent in Newest MM Practice Guidelines

July 31st 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis
December 7th 2018

Ruxolitinib Results in Better Treatment Response, Less Toxicity in Early Primary Myelofibrosis

Jaime Rosenberg
According to a study presented at the 60th American Society of Hematology Annual Meeting & Exposition, held December 1-4 in San Diego, California, a World Health Organization–defined diagnosis of primary myelofibrosis may help better identify patients who may need strict monitoring during treatment with ruxolitinib.
FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation
December 3rd 2018

FDA Approves Targeted Drug to Treat Relapsed or Refractory AML With FLT3 Mutation

Laura Joszt, MA
Once-daily gilteritinib pills have been approved to treat adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. Approximately 25% to 30% of patients with AML have this mutation, which is associated with an aggressive form of the disease and carries a higher risk of relapse.
Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse
December 1st 2018

Epigenetic Changes Are the Main Contributor to Immune Escape in Posttransplantation AML Relapse

David Bai, PharmD
In patients who relapse after allogeneic hematopoietic stem-cell transplantation, the therapeutic benefits that transplantation provide is diminished through mechanisms that remain unclear. A new study analyzed the genetic and epigenetic alterations of leukemic cells to determine any common features of relapse after transplantation
FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML
November 27th 2018

FDA Approves 2 Treatments in Older Adults With Newly Diagnosed AML

Laura Joszt, MA
FDA has recently approved 2 new treatments for patients age 75 and older who are newly diagnosed with AML and have other chronic health conditions or diseases that may mean they cannot use intensive chemotherapy.
Site Logo
November 27th 2018

Research to Look Out for at ASH 2018

Jaime Rosenberg
From December 1-4, hematology professionals from across the globe will convene in San Diego, California for the American Society of Hematology annual meeting to present and discuss their research and latest developments in malignant and non-malignant hematology. Here’s what to look out for during the meeting.
AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B
November 23rd 2018

AMT-061 Achieves Sufficient Increases in Factor IX Levels for Patients With Hemophilia B

David Bai, PharmD
AMT-061, an AAV5 vector containing factor IX (FIX)-Padua variant, has been shown to increase FIX activity to threshold FIX levels sufficient to significantly reduce the risk of bleeding events without the risk of adverse immune reactions.
Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease
November 20th 2018

Investigational Drug Gives Hope to Patients With Rare but Aggressive Blood Disease

Laura Joszt, MA
A new investigational drug has demonstrated high response rates in patients with a rare but highly aggressive blood disease that currently has no approved therapies, according to new research led by investigators at The University of Texas MD Anderson Cancer Center.
Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy
November 17th 2018

Dr Brian Koffman Highlights the Benefits and Risks of CAR T Therapy

Since chimeric antigen receptor (CAR) T-cell therapy is still in early development there are benefits and risks that eligible patients will have to weigh, including the durable response against the limited amount of data and toxic side effects, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma
November 17th 2018

FDA Gives Speedy Approval to Brentuximab for Peripheral T-Cell Lymphoma

Allison Inserro
The FDA announced Friday it expanded the approved use of brentuximab vedotin (Adcetris) in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma, using a new review process designed to increase efficiency.
CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma
November 15th 2018

CD47 Antibody With Rituximab Produces Durable Response in R/R Lymphoma

David Bai, PharmD
When used in combination with rituximab, Hu5F9-G4 (5F9), a humanized monoclonal anti-CD47 antibody, promotes durable objective and complete response rates in lymphoma while also having minimal adverse events (AE), according to a phase 1b study published in New England Journal of Medicine.
Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers
November 13th 2018

Cost Burden for Patients With Blood Cancers Eclipses the Burden in Other Cancers

Laura Joszt, MA
Patients with blood cancers are burdened with higher costs than patients with other cancers, and spending in blood cancers does not return to precancer levels, according to a new study from the Leukemia & Lymphoma Society.
Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma
November 7th 2018

Early Access to Daratumumab Confirms Safety in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
Daratumumab, a human CD38-directed monoclonal antibody, has been confirmed as safe in a population of heavily pretreated patients with multiple myeloma who received access to the treatment before the medication was commercially available, according to an early access treatment protocol study published in Cancer.
ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens
November 7th 2018

ALL Treatment May Increase Weight Gain, Suppress Growth in Children, Teens

David Bai, PharmD
Children and adolescents with acute lymphoblastic leukemia (ALL) face an increased risk of obesity and growth impairment from the disease and during ALL treatment, regardless of exposure to cranial irradiation, according to a recent study.
Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types
November 2nd 2018

Leukemia Survival Improved From 1995 to 2009, but Racial Gaps Increased for Some Types

Laura Joszt, MA
While survival from leukemia improved among adults from 1995 to 2009, and the survival gap between sexes decreased, the racial gap did not, according to new research published in Cancer.
Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma
October 31st 2018

Authors Find Brentuximab Vedotin Cost-Effective for Treatment of Advanced Hodgkin Lymphoma

Mary Caffrey
The analysis comes amid a debate set off when CVS Caremark announced that it would allow self-funded insurers to exclude drugs that entered the market above $100,000 per quality-adjusted life year.
The Evolution of CLL Testing and Treatment Over the Past Decade
October 30th 2018

The Evolution of CLL Testing and Treatment Over the Past Decade

Laura Joszt, MA
In the last decade, testing for and treatment of chronic lymphocytic leukemia (CLL) had undergone substantial changes with new testing that can personalize therapy and new agents that provide more clinical benefit.
Site Logo
October 25th 2018

Massachusetts Medicaid Finds CAR T-Cell Payment Solution While Waiting on CMS

Mary Caffrey
A life-saving therapy is challenging to administer and poses financial risks for patients and institutions alike. Speakers at the Academy of Managed Care Pharmacy Nexus 2018 address some approaches to paying for it while CMS develops long-term policies.
Site Logo
October 24th 2018

Study Summary: Amrubicin, Lenalidomide, and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Dinner S, Dunn TJ, Price E, et al. A phase I, open-label, dose-escalation study of amrubicin in combination with lenalidomide, weekly dexamethasone in previously treated adults with relapsed or refractory multiple myeloma. Int J Hematol. 2018, 108(3):267-273. doi: 10.1007/s12185-018-2468-5.
Site Logo
October 24th 2018

Study Summary: Response and Progression-Free Survival at 18 Months With Lenalidomide and Dexamethasone

Dimopoulos M, Wang M, Maisnar V, et al. Response, progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study. J Hematol Oncol. 2018, 11(1):49. doi: 10.1186/s13045-018-0583-7.
Site Logo
October 24th 2018

Study Summary: Once-Weekly Versus Twice-Weekly Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma: ARROW Interim Analysis

Moreau P, Mateos MV, Berenson JR, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed, refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018, 19(7):953-964. doi: 10.1016/S1470-2045(18)30354-1.
Site Logo
October 24th 2018

Study Summary: Ixazomib, Cyclophosphamide, and Dexamethasone for Previously Untreated Symptomatic Multiple Myeloma

Kumar SK, Buadi FK, LaPlant B, et al. Phase 1/2 trial of ixazomib, cyclophosphamide, dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J. 2018, 8(8):70. doi: 10.1038/s41408-018-0106-3.
One Gene Could Be Responsible for Acute Myeloid Leukemia
October 21st 2018

One Gene Could Be Responsible for Acute Myeloid Leukemia

Laura Joszt, MA
The EVI1 gene may be single-handedly at fault for acute myeloid leukemia, according to research published in Nature Communications.
Site Logo
October 18th 2018

Study Summary: Cardiovascular Safety Profile of Carfilzomib in Multiple Myeloma Clinical Trials

Chari A, Stewart AK, Russell SD, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. Blood advances. 2018, 2(13):1633-1644. doi: 10.1182/bloodadvances.2017015545.
Site Logo
October 18th 2018

Study Summary: Carfilzomib + Dexamethasone Versus Bortezomib (SC or IV) + Dexamethasone in Relapsed or Refractory Multiple Myeloma (ENDEAVOR Secondary Analysis)

Goldschmidt H, Moreau P, Ludwig H, et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma. 2018, 59(6):1364-1374. doi: 10.1080/10428194.2017.1376743.
Site Logo
October 18th 2018

Study Summary: Ibrutinib Plus Carfilzomib for Relapsed or Relapsed/Refractory Multiple Myeloma

Chari A, Larson S, Holkova B, et al. Phase 1 trial of ibrutinib carfilzomib combination therapy for relapsed or relapsed and refractory multiple myeloma [published online April 4, 2018]. Leuk Lymphoma. 2018:1-7. doi: 10.1080/10428194.2018.1443337.
Site Logo
October 18th 2018

Study Summary: The Role of Race and Ethnicity in Disease and Outcome Disparities in Multiple Myeloma

Ailawadhi S, Jacobus S, Sexton R, et al., outcome disparities in multiple myeloma: exploring the role of race/ethnicity in the Cooperative Group clinical trials. Blood Cancer J. 2018, 8(7):67. doi: 10.1038/s41408-018-0102-7.
Giant Acute Myeloid Leukemia Data Set Offers a Leap Forward in Matching Therapies to Patients
October 18th 2018

Giant Acute Myeloid Leukemia Data Set Offers a Leap Forward in Matching Therapies to Patients

Mary Caffrey
Researchers have created a database that shows how 409 different tumor cells respond to 122 therapies, which will allow clinical trials to proceed for this aggressive blood cancer.
Three Genetic Types Drive Higher Prevalence of MM in African Americans
October 14th 2018

Three Genetic Types Drive Higher Prevalence of MM in African Americans

Laura Joszt, MA
Multiple myeloma (MM) occurs 2 to 3 times more frequently in Americans of African descent than in Americans of European descent, and a new study has identified 3 gene types that account for this disparity.
Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds
October 11th 2018

Tisagenlecleucel's High Price Aligns With Its Benefit in Pediatric B-ALL, Study Finds

Laura Joszt, MA
Tisagenlecleucel's high price is aligned with the benefit the chimeric antigen receptor T-cell therapy provides over a patient's life. Approximately 40% of patients treated are expected to be long-term survivors.
Can Flipping a Genetic Switch Help Treat a Common Childhood Leukemia?
October 10th 2018

Can Flipping a Genetic Switch Help Treat a Common Childhood Leukemia?

Mary Caffrey
Research at the University of Washington is exploring the possibility of triggering one gene to take over the function of another with a common mutation that triggers acute lymphoblastic leukemia.
<1
...
151617181920212223
...
28>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo